BioCentury
ARTICLE | Clinical News

PharmaMar's Zepsyre misses in Phase III for platinum-resistant ovarian cancer

January 26, 2018 8:12 AM UTC

PharmaMar S.A. (Madrid:PHM) said Zepsyre lurbinectedin (PM01183, PM1183) missed the primary endpoint of improving progression-free survival (PFS) vs. topotecan or pegylated liposomal doxorubicin in the Phase III CORAIL trial to treat platinum-resistant ovarian cancer. The company said PFS was the same in all three treatment arms, but did not disclose details or next steps. Data are slated to be presented at a future cancer conference.

The open-label, U.S. trial’s secondary endpoints include overall survival (OS), patient-reported outcomes and overall response rate (ORR)...